CNC Stock Analysis — Centene Corporation
Sector: Healthcare
AI Verdict
Centene trades at 18.9x next year's earnings—cheap for a healthcare stock growing revenues at 17% if its government contract moat holds up.
Competitive Moat
Centene operates as a managed care organization specializing in government-sponsored healthcare programs such as Medicaid and Medicare Advantage, which creates high regulatory and administrative barriers for new entrants. Its scale and expertise in navigating complex state and federal contracts provide a durable edge over smaller competitors.
Summary
Centene's 102.82% one-year return stands out as Medicaid and Medicare contracts drive rapid scale.
Where It Stands
Centene has delivered a 102.82% one-year return, trades at 18.9x forward earnings versus the healthcare sector median of 22x, and its RSI of 57.8 signals neutral momentum.
Key Metrics
- RSI: 57.8 — Neutral
- Forward P/E: 18.9x
- Revenue Growth: +0.2%
- Market Cap: $32.6B
- 1-Year Return: 102.82%
- 52-Week High: $69.29
- 52-Week Low: $25.08
Analyst Consensus
11 Buy · 15 Hold · 1 Sell (27 analysts)
Bull Case
With 17.0% trailing revenue growth and a forward P/E of 18.9x, investors are getting double-digit top-line expansion at a discount to the sector average multiple.
Bear Case
If the forward P/E compresses from 18.9x to the sector median of 22x, upside is limited and any RSI move above 65 could trigger a pullback.
Catalyst to Watch
Watch for upcoming state Medicaid contract awards or renewals, as wins or losses here directly impact growth expectations.